Surface Modification of Bi2O3 Nanoparticles with Biotinylated β-Cyclodextrin as a Biocompatible Therapeutic Agent for Anticancer and Antimicrobial Applications

Molecules. 2023 Apr 20;28(8):3604. doi: 10.3390/molecules28083604.

Abstract

Bismuth oxide nanoparticles with appropriate surface chemistry exhibit many interesting properties that can be utilized in a variety of applications. This paper describes a new route to the surface modification of bismuth oxide nanoparticles (Bi2O3 NPs) using functionalized beta-Cyclodextrin (β-CD) as a biocompatible system. The synthesis of Bi2O3 NP was done using PVA (poly vinyl alcohol) as the reductant and the Steglich esterification procedure for the functionalization of β-CD with biotin. Ultimately, the Bi2O3 NPs are modified using this functionalized β-CD system. The particle size of the synthesized Bi2O3 NPs is found to be in the range of 12-16 nm. The modified biocompatible systems were characterized using different characterization techniques such as Fourier transform infrared spectroscopy (FTIR), transmission electron microscopy (TEM), scanning electron microscopy (SEM), X-ray powder diffraction (XRD) and Differential Scanning Calorimetric analysis (DSC). Additionally, the antibacterial and anticancerous effects of the surface-modified Bi2O3 NP system were also investigated.

Keywords: antibacterial; anticancerous studies; beta-cyclodextrin; biotin; bismuth oxide nanoparticles.

MeSH terms

  • Anti-Infective Agents*
  • Bismuth / pharmacology
  • Nanoparticles* / chemistry
  • Spectroscopy, Fourier Transform Infrared
  • X-Ray Diffraction
  • beta-Cyclodextrins* / chemistry

Substances

  • bismuth oxide
  • Anti-Infective Agents
  • Bismuth
  • beta-Cyclodextrins

Grants and funding

This research received no external funding.